CSI Market
Sign In | Register

Redhill Biopharma Ltd (RDHL) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access RDHL Annual Balance Sheets →
The balance sheet figures below highlight longer-term patterns in how Redhill Biopharma Ltd finances operations and invests in assets.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
0 0 0 (Dec 31 2024)
Assets
Cash And Cash Equivalents3.97
Cash & Short-term Investments3.00
Accounts receivable0.08
Trade & Other Current Receivables (IFRS combined total)-
Inventories0.00
Other Current Assets2.48
Total Current Assets6.53
Equipment/Property/Plant Net0.05
Intangible Assets0.00
Other Assets, Noncurrent18.77
Total Assets25.35
Liabilities
Accounts Payable0.00
Other Liabilities, Current19.22
Total Current Liabilities19.22
Total Long-term Debt0.00
Other liabilities, Noncurrent1.86
Total Liabilities21.08
Stockholders' Equity
Other Equity4.27
Common Stockholder's Equity4.27
Total Stockholder's Equity4.27
Liabilities & Stockholder's Equity25.35
4 historic quarters locked

Sign in to unlock the full Redhill Biopharma Ltd balance sheet history.

Sign In Create Free Account

About Redhill Biopharma Ltd Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 20-F filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001104659-26-049055

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.